HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

P&G/Wella deal

This article was originally published in The Rose Sheet

Executive Summary

Procter & Gamble's $67.65 (€1= $1.10) offer for Wella preference shares is low and should be increased 30%-50% to be more in line with the $101.48 bid made for Wella's ordinary shares, German accounting firm Susat & Partner says. Susat recently filed a complaint with German financial and securities regulator BaFin on behalf of an investor who holds 5% of Wella preferred shares. P&G maintains its bid is "fair and attractive," as it is 8% higher than the stock's three month premium prior to the acquisition. Henkel bought a 6.86% share in the hair care firm including 10.38% of Wella's preference shares days before P&G announced plans to acquire the company (1"The Rose Sheet" March 17, 2003, p. 4). At an analyst meeting April 14, Henkel CEO Ulrich Lehner stated, "Against the background of the price offered for the ordinary shares, the offer for the preferred shares appears to be very low"...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS011162

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel